Substance and claimed effects

Serum ferritin and transferrin saturation (TSAT) are the two routinely measured biomarkers of systemic iron status. Ferritin is the intracellular iron-storage protein; circulating ferritin reflects the size of total body iron stores at steady state, with each 1 ng/mL of serum ferritin corresponding to approximately 8–10 mg of stored iron in healthy adults Camaschella 2015. TSAT is calculated as serum iron divided by total iron-binding capacity (TIBC), expressed as a percentage; it reflects the fraction of transferrin currently loaded with iron and is thus a measure of iron available for delivery to erythron and tissues Pasricha et al. 2021. The clinical claim addressed by this entry is that ferritin and TSAT, interpreted together (and with a C-reactive protein when inflammation is plausible), reliably classify a patient into one of four states — replete, iron deficient (with or without anemia), iron sequestered by inflammation (anemia of chronic disease / functional iron deficiency), or iron overloaded — and that this classification then drives correct decisions about supplementation, parenteral iron, phlebotomy, and the dosing target for restless legs syndrome. Consequences this entry covers holistically: detection and correction of overt and latent iron deficiency (energy, focus, exercise capacity, mood, hair density, post-partum cognition); the iron-RLS axis (sleep architecture, periodic limb movements); detection of HFE-related hereditary hemochromatosis (longevity via prevention of cirrhosis, hepatocellular carcinoma, cardiomyopathy, diabetes); and avoidance of inappropriate iron supplementation in those who do not need it.

Evidence by addressing question

Mechanism

Ferritin is a 24-subunit hollow protein (H- and L-chain heteropolymers) that sequesters up to ~4 500 iron atoms per molecule as a ferrihydrite mineral, neutralizing iron's redox toxicity Camaschella 2015. A small fraction is secreted into plasma (the L-chain–rich, mostly iron-poor "serum ferritin"), and that secreted pool tracks total body iron under steady-state conditions. The mechanism that complicates interpretation: ferritin is also an acute-phase reactant. Hepatic ferritin synthesis is upregulated by IL-6 and other inflammatory cytokines independently of iron stores, so any inflammatory, infectious, hepatic, or malignant process can elevate serum ferritin two- to three-fold even when stores are depleted Dignass et al. 2018Daru et al. 2017. Obesity, alcoholic and non-alcoholic fatty liver disease, and metabolic syndrome reliably raise ferritin via low-grade hepatic inflammation without iron overload.

TSAT reflects the dynamic balance between iron supply and demand. Iron exported from enterocytes and macrophages by ferroportin is bound by transferrin in plasma; transferrin normally runs about 20–45% saturated. In iron deficiency, transferrin synthesis is upregulated (TIBC rises) and serum iron falls, dropping TSAT below 20%. In iron overload, transferrin saturates with iron and TSAT rises above 45%, with the excess "non-transferrin-bound iron" being the toxic species that accumulates in hepatocytes, cardiomyocytes, and pancreatic β-cells Powell et al. 2016. In inflammation, hepcidin (the master iron regulator, also induced by IL-6) blocks ferroportin, trapping iron inside enterocytes and macrophages: TIBC falls, serum iron falls, and TSAT typically lands low — but ferritin is high because macrophage iron is being stored rather than released. This is the signature of anemia of chronic disease and the reason ferritin alone cannot diagnose deficiency in a sick patient Dignass et al. 2018.

The brain has its own iron-handling system, separated by the blood–brain barrier and dependent on transferrin-receptor-mediated transport across the choroid plexus and brain endothelium. Cerebrospinal-fluid ferritin and substantia nigra MRI iron quantification show that brain iron is reduced in restless legs syndrome even when peripheral ferritin is well within the "normal" reference range, and post-mortem work in RLS shows defective iron acquisition by neurons rather than dietary deficiency Connor et al. 2003Earley et al. 2014. This is the mechanistic basis for the IRLSSG's serum-ferritin target of >75 ng/mL for RLS treatment — well above the standard "iron-deficient" threshold — because peripheral status has to be supranormal before brain iron repletes.

Evidence (does this work)

Ferritin is the single most informative biomarker for detecting iron deficiency in otherwise healthy patients. A Cochrane systematic review of 72 diagnostic-accuracy studies found that serum ferritin had a pooled sensitivity of ~82% and specificity of ~76% for iron deficiency at the conventional 30 ng/mL cut-off, with area-under-curve typically >0.9 against bone-marrow iron staining as the reference standard Garcia-Casal et al. 2021. The historical WHO cut-off of <15 ng/mL is highly specific but misses many deficient patients; physiological calibration against NHANES hemoglobin and sTfR data places the true threshold for iron-deficient erythropoiesis at 25–30 ng/mL in non-pregnant women and children, and the WHO 2020 guideline revised the threshold upward to 15 ng/mL still for population surveillance but acknowledged the clinical inflection at ~30 ng/mL Mei et al. 2021WHO 2020.

Pairing TSAT with ferritin recovers cases ferritin alone misses. In inflammation, ferritin can be normal or high while TSAT remains diagnostic (low). The standard hematology rule used in the AASLD and EASL guidelines for hereditary hemochromatosis screening — fasting TSAT >45% in either sex, with ferritin then used to gauge iron load and disease stage — was set by the HEIRS study (n=99 711 primary-care adults across the US and Canada), which demonstrated TSAT's superiority to ferritin as a screening test for HFE C282Y homozygosity Adams et al. 2005Bacon et al. 2011EASL 2010.

Treatment of iron deficiency reverses symptoms across multiple endpoints. Krayenbühl et al. randomized 90 non-anemic premenopausal women with ferritin <50 ng/mL and fatigue to IV iron sucrose or placebo; fatigue scores improved by 1.1 points on a 10-point scale (p<0.001) at 6 weeks in the iron arm, with ferritin rising to >100 ng/mL Krayenbühl et al. 2011. A systematic review of non-anemic iron deficiency confirmed the pattern across 14 trials: oral or IV iron consistently improved fatigue, exercise tolerance, and cognitive endpoints in patients with ferritin below 30–50 ng/mL even when hemoglobin was normal Pratt and Khan 2016. In RLS, the IRLSSG 2018 task force assembled 15 RCTs and case-series supporting target ferritin >75 ng/mL and TSAT >20%; oral iron with vitamin C, taken on alternate days, was first-line, and IV ferric carboxymaltose was effective in oral-refractory or severe cases Allen et al. 2018Aurora et al. 2012.

Hereditary hemochromatosis evidence: untreated HFE C282Y homozygotes diagnosed with cirrhosis or diabetes had ~50% 10-year mortality in the historical Düsseldorf cohort; those diagnosed before end-organ damage and treated with serial phlebotomy had survival indistinguishable from the general population Niederau et al. 1996. The genetic prevalence is ~1 in 200 to 1 in 300 in northern European-descent populations, with phenotypic expression in 10–30% of homozygotes — making it among the most common Mendelian disorders, and ferritin/TSAT the only practical population-level case-finding tool short of universal genotyping.

Protocol (interpretation and supplementation)

Standard panel: serum ferritin, serum iron, TIBC (or transferrin, from which TSAT is calculated as serum iron ÷ [transferrin × 1.42] × 100), with C-reactive protein when inflammation is plausible (chronic illness, recent infection, obesity, autoimmune disease). Fasting morning draw is preferred for TSAT because serum iron is highest in the morning and falls through the day, and recent dietary or supplemental iron can transiently elevate TSAT for several hours Camaschella 2015.

Decision matrix used in mainstream hematology Auerbach and Adamson 2016Camaschella 2015:

• Replete: ferritin 30–300 ng/mL (men) or 30–200 ng/mL (women), TSAT 20–45%, CRP normal.
• Iron deficient (otherwise healthy): ferritin <30 ng/mL with TSAT <20%. Treat regardless of hemoglobin if symptomatic.
• Functional iron deficiency / anemia of chronic disease: ferritin normal or elevated (up to ~500 ng/mL) but TSAT <20% with elevated CRP. Treat the underlying inflammation; IV iron if anemia is severe — oral iron is largely blocked by hepcidin.
• Possible iron overload: TSAT >45% (men) or >50% (women) on fasting repeat draw, with or without elevated ferritin. Refer for HFE genotyping and hepatic iron quantification.
• Inflammation without overload: isolated ferritin elevation (200–1 000 ng/mL) with normal TSAT and elevated CRP, or known fatty liver / metabolic syndrome. Address the driver; phlebotomy is not indicated.

RLS treatment thresholds differ: the IRLSSG targets serum ferritin >75–100 ng/mL and TSAT >20%, well above the deficiency cut-off, because brain iron is the relevant compartment Allen et al. 2018. First-line: oral ferrous sulfate 65 mg elemental iron with 100–200 mg vitamin C on alternate days; the Stoffel trials showed that alternate-day dosing roughly doubles fractional absorption versus daily dosing because each iron dose triggers a hepcidin spike that blocks the next day's absorption Stoffel et al. 2017. IV ferric carboxymaltose 750–1 000 mg single dose for oral failure, severe deficiency, or refractory RLS.

Contraindications

The decisive contraindication to empirical iron supplementation is undiagnosed hereditary hemochromatosis. With HFE C282Y homozygote prevalence around 1 in 200 in northern European-descent populations and another ~10% heterozygotes, blanket "everyone could use a multivitamin with iron" advice meaningfully accelerates iron overload in this subgroup Adams et al. 2005. Post-menopausal women and adult men with iron deficiency require evaluation for occult GI bleeding (colon cancer, peptic ulcer, celiac disease, H. pylori) before chronic supplementation — repleting stores without finding the source delays cancer diagnosis Camaschella 2015. Anemia of chronic disease should not be treated with empirical oral iron — hepcidin blocks absorption, supplementation is ineffective, and unabsorbed iron may worsen gut dysbiosis. Inflammatory bowel disease in flare is an indication for IV rather than oral iron. Pregnancy raises ferritin thresholds (deficiency cut-off rises to ~30 ng/mL in trimester one but stores naturally fall by trimester three; obstetric protocols apply) and is its own clinical pathway.

Misconceptions

The dominant clinical misconception is that ferritin alone diagnoses iron status. In a healthy outpatient with no inflammation, this approximates the truth; in anyone with obesity, fatty liver, alcohol use, autoimmune disease, kidney disease, malignancy, or recent infection, ferritin can be normal or elevated despite frank iron deficiency, and TSAT plus CRP are required to disentangle Dignass et al. 2018Daru et al. 2017. The second misconception is that "low-normal" ferritin (e.g. 30–50 ng/mL) is reassuring. Symptomatic patients with ferritin in this range can have iron-deficient erythropoiesis without anemia and respond to treatment; the practical threshold for symptomatic non-anemic iron deficiency is closer to 50 ng/mL in men and 30 ng/mL in women, with RLS patients targeted above 75 ng/mL Pratt and Khan 2016Allen et al. 2018. The third misconception, prevalent in longevity-oriented communities, is that ferritin >100 ng/mL itself is "iron toxicity" warranting phlebotomy. Without elevated TSAT, modestly elevated ferritin most often reflects inflammation, not stored iron; phlebotomy in this setting does not address the driver and depletes useful stores. Phlebotomy is indicated for documented overload (high TSAT, hepatic iron concentration above threshold) or treatment of confirmed hemochromatosis, not for ferritin numbers in isolation Bacon et al. 2011.

Audience and population variability

Premenopausal women (10–15% prevalence of iron deficiency in high-income countries; up to 40% with heavy menstrual bleeding), pregnant women (~25–40% by trimester three even when supplemented), endurance athletes (especially female; foot-strike hemolysis, sweat losses, and inflammation-driven hepcidin elevation lower iron utilization), vegetarians and vegans (non-heme iron has ~5–10% bioavailability vs ~25% heme), frequent blood donors (each whole-blood donation depletes ~200–250 mg iron), and infants of iron-deficient mothers carry the highest baseline risk and have the most to gain from testing Pasricha et al. 2021Clénin et al. 2015. Men and post-menopausal women have low baseline risk; iron deficiency in this group is a sentinel finding that warrants GI work-up. HFE C282Y homozygotes (predominantly northern European descent) are the inverse population — at risk of overload, not deficiency, and benefit from ferritin/TSAT-based case-finding from age 18–30. Black, Hispanic, and East Asian populations have lower C282Y prevalence and higher background ferritin partly reflecting differences in inflammatory burden rather than iron stores; race-blind reference intervals can both under- and over-diagnose.

Failure modes

The most common failure modes seen in practice: (1) ordering ferritin alone and missing functional iron deficiency in inflammatory states; (2) interpreting ferritin against the lab's reference range (often "12–300 ng/mL") rather than the physiological threshold, missing symptomatic deficiency at ferritin 15–30; (3) prescribing daily oral iron without recognizing the hepcidin-driven absorption block — Stoffel showed that alternate-day, single morning dosing nearly doubles iron absorbed per dose compared with twice-daily or consecutive-day regimens Stoffel et al. 2017; (4) co-administering iron with calcium, dairy, tea, coffee, or proton-pump inhibitors, blocking absorption; (5) accepting "tolerable" GI side effects of high-dose ferrous sulfate when ferrous bisglycinate or alternate-day dosing would deliver more iron with less nausea; (6) treating RLS with dopamine agonists without first measuring and correcting ferritin to >75 ng/mL, missing the underlying cause and risking long-term augmentation Allen et al. 2018.

Practicalities

Ferritin, serum iron, TIBC, and CRP are inexpensive routine assays available through any clinical laboratory; in the US, the ferritin + iron studies + CRP panel runs roughly $30–80 cash-pay through direct-to-consumer labs and is usually covered by insurance when ordered for fatigue, anemia work-up, or RLS. Fasting morning draw improves TSAT accuracy. Patients should hold iron supplements for 24 hours before the draw to avoid spurious TSAT elevation. Oral iron repletion typically takes 3–6 months once a working dose is identified; recheck ferritin at 3 months to confirm trajectory. IV iron repletes stores in a single infusion but requires clinic time and carries a low rate of mild infusion reactions; modern formulations (ferric carboxymaltose, ferric derisomaltose) have largely eliminated the older anaphylaxis concerns of high-molecular-weight iron dextran Auerbach and Adamson 2016.

Stakes

Persistent untreated iron deficiency causes chronic fatigue, exercise intolerance, cognitive blunting, hair shedding, restless legs, postpartum depression and impaired infant cognitive development through the mother, and in older adults contributes to falls and excess mortality Beard et al. 2005Pasricha et al. 2021. Persistent untreated iron overload from hereditary hemochromatosis causes cirrhosis, hepatocellular carcinoma (relative risk ~20-fold in cirrhotic hemochromatotics), diabetes, dilated cardiomyopathy, hypogonadism, and arthropathy — all preventable by early phlebotomy Niederau et al. 1996Powell et al. 2016.

Payoff

Repletion of iron deficiency in symptomatic patients produces measurable improvements in fatigue scores within 6–12 weeks, hemoglobin recovery within 8–12 weeks, hair shedding reduction over 3–6 months, and RLS symptom remission in roughly 60% of iron-treated patients when ferritin is brought above 75 ng/mL Krayenbühl et al. 2011Allen et al. 2018. For hereditary hemochromatosis caught before cirrhosis, life expectancy equals that of the general population Niederau et al. 1996.

The credibility range

Optimist case

Ferritin and TSAT are among the most clinically validated biomarkers in medicine, with multiple international guidelines (AASLD, EASL, BSH, NICE, IRLSSG, WHO) converging on substantially similar interpretive frameworks, a Cochrane systematic review supporting ferritin's discriminatory accuracy for deficiency, and two of the largest population-screening studies in hematology (HEIRS for hemochromatosis, NHANES for deficiency) supporting the cut-offs in routine use Garcia-Casal et al. 2021Adams et al. 2005. Treatment of identified deficiency reverses the symptom in well-designed RCTs even in non-anemic patients, and treatment of identified overload prevents otherwise-inevitable end-organ damage. Cost is trivial, harms are negligible, and the test changes management in a meaningful subset of patients with fatigue, RLS, exercise underperformance, hair loss, or family history of hemochromatosis.

Skeptic case

Ferritin's interpretive complexity is not trivial: the assay is reliable but the physiological meaning depends on inflammation, hepatic status, and recent dietary intake. The "right" cut-off has drifted across decades (15 vs 30 vs 50 ng/mL), reflecting genuine uncertainty about where symptomatic deficiency begins; the WHO and IRLSSG and routine clinical labs do not agree Mei et al. 2021. The RCT base for treating non-anemic iron deficiency in symptomatic adults is thinner than the enthusiasm of the wellness community suggests — most trials are small, single-center, and short-duration, and placebo effects on fatigue are substantial. Universal hereditary hemochromatosis screening of adults of European descent has not been adopted by USPSTF because the absolute number of cases prevented per screened person is modest and overdiagnosis (homozygotes who would never have developed disease) is real, with penetrance estimates as low as 10% for clinical disease. In the longevity-supplement subculture, the test is sometimes used to justify aggressive phlebotomy for asymptomatic ferritin elevations that simply reflect metabolic syndrome — actively unhelpful.

Author's call

This is settled hematology with active edges. The framework — ferritin plus TSAT, interpreted against an inflammation marker, with established cut-offs — is correct and supported by guidelines on three continents. The active edges are the right cut-off for symptomatic non-anemic deficiency (clinical consensus migrating from 15 to 30 to sometimes 50 ng/mL), the right population for screening (universal in pregnancy and high-risk groups, individualized in symptomatic adults, contested in asymptomatic general adults), and the proper interpretive weight to give modestly elevated ferritin in the absence of high TSAT. Entry treats ferritin + TSAT (with CRP when relevant) as the correct test, frames the cut-offs as the IRLSSG/AASLD ranges, and explicitly warns against ferritin-alone interpretation and against phlebotomy for inflammation-driven hyperferritinemia. evidence scored 4 (multiple guidelines, replicated cohorts, but interpretation contested at the margins). controversy scored 2 (cut-offs and screening contested; the framework itself is not).

Stakeholder and incentive map

• Hematology and hepatology guideline bodies (AASLD, EASL, BSH, IRLSSG, AASM, WHO) — the orthodox center of gravity. Set cut-offs, define the panel, write the treatment guidelines. Conservative on screening asymptomatic populations.
• Endurance sports medicine (USOC, IOC, Swiss sports-medicine consortium) — early and aggressive adopters of ferritin testing in athletes; helped establish the symptomatic-non-anemic-deficiency literature Clénin et al. 2015.
• Iron and IV-iron manufacturers (Vifor/CSL, AMAG, Pharmacosmos) — commercial interest in expanding ferritin screening and lowering treatment thresholds; sponsor much of the modern IV-iron trial base.
• Direct-to-consumer lab companies (Quest, Labcorp, InsideTracker, Marek Health) — sell ferritin/iron panels to consumers; reasonable utility, occasional over-interpretation in marketing.
• Hereditary hemochromatosis advocacy (Iron Disorders Institute, Haemochromatosis UK) — push earlier and broader case-finding; partly responsible for the AASLD's expanded screening criteria.
• Longevity/biohacker subculture — heterogeneous; one camp emphasizes iron-deficiency identification (correct), another emphasizes "iron toxicity" and prescribes phlebotomy for modestly elevated ferritin (frequently incorrect when TSAT is normal).
• USPSTF and conservative screening bodies — counterweight; have declined to recommend universal screening of asymptomatic adults for either deficiency (outside pregnancy) or overload, reflecting real uncertainty about the absolute benefit.

Population variability

Iron-deficiency prevalence varies sharply by life stage and behavior. Premenopausal women in high-income countries: 10–15% iron deficient, 3–5% anemic; with heavy menstrual bleeding the figures double or triple Pasricha et al. 2021. Pregnancy: stores naturally decline; ~30–40% of third-trimester women are iron deficient even in well-resourced settings, and WHO recommends universal supplementation. Vegans and vegetarians: ferritin runs 30–50% lower than omnivores on average due to non-heme iron's lower bioavailability and dietary inhibitors (phytate, polyphenols). Endurance athletes: female endurance athletes have a 20–35% prevalence of low ferritin even without anemia; the mechanism is multifactorial (hepcidin elevation post-exercise, sweat losses, foot-strike hemolysis, GI microbleeding from NSAIDs) Clénin et al. 2015. Frequent blood donors: each whole-blood donation depletes ~200–250 mg iron; donors at >3 donations per year predictably develop deficiency without supplementation. Older adults (>65): iron deficiency is rarely nutritional; sentinel finding for occult GI malignancy or chronic blood loss. HFE C282Y homozygotes: 1 in 200 to 1 in 300 in northern European descent, near-zero in sub-Saharan African and East Asian populations; phenotypic penetrance 10–30% but higher in men and in those who drink heavily. Ferritin reference intervals also vary by ethnicity (Black and Hispanic Americans run higher ferritin on average partly from higher chronic-inflammation burden, not higher iron stores), and lab reference ranges that ignore this can mislead.

Knowledge gaps

The optimal serum ferritin threshold for symptomatic non-anemic iron deficiency remains undefined — clinicians use values between 30 and 100 ng/mL depending on the population, and large RCTs with hard symptomatic endpoints (fatigue, exercise capacity, cognitive performance) at different cut-offs would settle the question. The clinical value of universal hereditary hemochromatosis genetic screening in northern European populations is unresolved; the modest absolute benefit, combined with overdiagnosis from low-penetrance homozygotes, has kept USPSTF from recommending it, but cheaper genotyping is changing the cost-benefit calculation. Brain-iron measurement (transcranial sonography or quantitative susceptibility MRI) is more sensitive than serum ferritin for RLS but is not routinely available; whether peripheral targets above 75 ng/mL are sufficient for all RLS phenotypes is uncertain. The role of soluble transferrin receptor (sTfR) and the sTfR/log-ferritin index for disentangling deficiency from anemia of chronic disease has solid trial backing but limited routine availability outside academic centers Dignass et al. 2018. Finally, the long-term effects of repeated IV-iron dosing in non-anemic patients with chronic fatigue are not yet established; clinically meaningful safety signals have not emerged, but the practice has scaled faster than the long-horizon data.

Scope vs brief. The brief named ferritin, TSAT, inflammation markers, iron deficiency, iron overload, restless legs, and supplementation decisions. The article covers all of these; no consequence was dropped. Inflammation markers are folded into the protocol as a CRP add-on (the routinely available proxy) rather than detailed coverage of sTfR / hepcidin assays, which are not widely available outside academic centers.

Hard scoping calls.

• Held pregnancy-specific iron supplementation protocols out — trimester-specific cut-offs, IV iron decisions in pregnancy, fetal-development implications deserve their own entry under the obstetric umbrella.
• Held pediatric iron deficiency out — different reference ranges, neurodevelopmental stakes, screening cadence; separate-entry candidate.
• Held the iron-deficiency-vs-thalassemia-trait differential out — needs hemoglobin electrophoresis and is genuinely a hematologist's call, not a Body Handbook reader's decision.
• Mentioned soluble transferrin receptor (sTfR) in the dossier but not the article — limited routine availability undercuts the reader-facing utility. Worth revisiting if direct-to-consumer labs add it.

Rating difficulties. Most benefit dimensions are contingent on actually being iron deficient. energy and health_short_term scored 4 on the basis that for the subgroup the test identifies (a real fraction of the population — premenopausal women, athletes, vegans, donors), repletion is genuinely floor-lifting; the score reflects what the substance does when applied to the people it's for, not a population-weighted expected value. longevity scored 3 rather than higher because the hemochromatosis catch is concentrated in a smaller subgroup and absolute numbers prevented are modest, even though the per-case effect is large.

Cadence choice. Picked as-needed over yearly: USPSTF declines to recommend universal annual ferritin screening in asymptomatic adults, and the real-world trigger pattern is symptoms (fatigue, RLS, hair shedding, exercise plateau), life-stage milestones (pregnancy planning, post-menopause), or known risk (vegan diet, regular donor, family history of hemochromatosis, endurance training block).

Contraindications field left empty. The hemochromatosis token in the closed vocabulary is a contraindication for empirical iron supplementation, not for the test itself — and the test is the substance. The relevant don't-take-iron warning is woven into the article body rather than the structured field, which would mis-signal that the test is risky.

Future-link candidates.

• Heavy menstrual bleeding — the single largest upstream driver of iron deficiency in premenopausal women.
• Hepcidin — the master regulator that explains alternate-day dosing and functional iron deficiency.
• Vitamin B₁₂ and folate — the other two macrocytic-anemia drivers that present with overlapping fatigue and cognitive symptoms.
• Sleep apnea / UARS — the differential for nocturnal sleep disruption when RLS is ruled out or iron is replete.
• Female athlete triad / RED-S — iron is one leg of a larger underfueling-and-hormonal-disruption pattern.
• Blood donation cadence — the trade-off between altruism and personal iron depletion in regular donors.

Separate-entry candidates. Restless legs syndrome itself as a standalone clinical entry (covering dopamine agonists, alpha-2-delta ligands, augmentation, sleep-pressure mechanisms); IV iron decision-making and infusion logistics; pediatric iron deficiency; iron-related performance in athletes.

Skeptic position acknowledged. The dossier's credibility range explicitly names USPSTF's decline to recommend universal hemochromatosis screening and the genuine cut-off uncertainty (15 vs 30 vs 50 ng/mL). Article lands in the IRLSSG / AASLD camp on cut-offs and treats high-risk-group screening as warranted, low-risk-group screening as symptom-triggered. Editor disagreement worth flagging if catalogue editorial leans more conservative on screening.